CPA’s submission, “Ensuring U.S. Sovereignty in North American Trade,” concludes that the current trilateral USMCA framework binds two vastly different economies to one unenforceable system—with each reliant on the far larger U.S. consumer market.
The report, titled “Section 232 Steel Tariffs are Necessary for National Security,” highlights how the Trump administration’s Section 232 tariffs have revitalized American manufacturing, created jobs, and strengthened national security.
KEY POINTS Beef prices are at record highs—not because of U.S. ranchers or tariffs, but because dependence on foreign imports and meatpacker consolidation have distorted
There are very few things that Democrats and Republicans agree on. One of them is the need to support domestic shipbuilding beyond just military vessels.
The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.
On the surface, America looks like an unrivaled success story. Yet beneath the headline numbers lies an economy increasingly dependent on foreign production, hollowed out in critical industries, and unable to provide secure, high-wage work for many of its citizens.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
This year, GM swapped positions with Ford. GM is the most exposed to China while Ford has declined to No. 5.
CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
